Blocking type 2 inflammation by dupilumab does not control classic (type 1‐driven) allergic contact dermatitis in chronic hand eczema

2019 ◽  
Vol 81 (2) ◽  
pp. 145-147 ◽  
Author(s):  
Marie‐Noëlle Crepy ◽  
Audrey Nosbaum ◽  
Lynda Bensefa‐Colas
Keyword(s):  
Contact Dermatitis ◽  
Allergic Contact Dermatitis ◽  
Hand Eczema ◽  
Chronic Hand Eczema ◽  
Allergic Contact ◽  
Type 2 Inflammation ◽  
Blocking Type

Allergic contact dermatitis caused by prednicarbate presenting as chronic hand eczema

2015 ◽  
Vol 73 (1) ◽  
pp. 51-52 ◽  
Author(s):  
María-Mercedes Otero-Rivas ◽  
Inmaculada Ruiz-González ◽  
Alicia Pérez-Bustillo ◽  
Manuel-Ángel Rodríguez-Prieto
Keyword(s):  
Contact Dermatitis ◽  
Allergic Contact Dermatitis ◽  
Hand Eczema ◽  
Chronic Hand Eczema ◽  
Allergic Contact

scholarly journals Common Contact Sensitizers among Patients with Hand Eczema: A Multicenter-Study in Nepal

2016 ◽  
Vol 14 (1) ◽  
pp. 14-17
Author(s):  
S. Bhattarai ◽  
A. Rijal ◽  
S. Agrawal
Keyword(s):  
Contact Dermatitis ◽  
Allergic Contact Dermatitis ◽  
Patch Test ◽  
Patch Testing ◽  
Potassium Dichromate ◽  
College Teaching ◽  
Hand Eczema ◽  
Contact Allergens ◽  
Allergic Contact

Introduction: Allergic contact dermatitis in Nepal is not an uncommon disorder. Patch testing is a well established method of diagnosing allergic contact dermatitis. Patients with contact dermatitis are well known to have impaired quality of life which often leads to frequent dermatological consultations.Objective: Lack of data from Nepal has prompted us to undertake this study with the aims to know the frequency of allergic contact dermatitis and the commonest contact allergens among the patients with Hand eczema attending the out-patient department of dermatology, B.P. Koirala Institute of Health Sciences and Kathmandu Medical College Teaching Hospital.Material and Methods: A total of 256 patients were included in the study. Out of them 195 with hand eczema agreed to participate and undergo patch testing. The antigens used included the Indian standard series of patch test allergens approved by Contact and Occupational Dermatoses Forum of India.Results: Hundred and ten cases (56.4%) were patch test positive (PTP) at 48 as well as 96 hours to at least one allergen. PTP was seen more commonly in females. The most common allergen in females was nickel sulphate followed by cobalt chloride, gentamicin and mercapto mix while males were positive to potassium dichromate, followed by epoxy resin, fragrance mix and nickel sulphate.Conclusion: Patch testing has proved a useful tool for the detection of allergic contact dermatitis and for identification of contact allergens. When positive reactions correlate with environmental exposure the test usually assists the physician in establishing the cause of dermatitis, hence treating the patients and improving their quality of life.Nepal Journal of Dermatology, Venereology & Leprology, Vol.14(1) 2016, pp.14-17

Allergic contact dermatitis in pediatric patients with type 1 diabetes: An emerging issue

2020 ◽  
Vol 162 ◽  
pp. 108089 ◽  
Author(s):  
Fortunato Lombardo ◽  
Giuseppina Salzano ◽  
Giuseppe Crisafulli ◽  
Ilenia Panasiti ◽  
Angela Alibrandi ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Contact Dermatitis ◽  
Allergic Contact Dermatitis ◽  
Pediatric Patients ◽  
Allergic Contact

Allergic contact dermatitis caused by glucose sensors in type 1 diabetes patients

2019 ◽  
Vol 81 (3) ◽  
pp. 161-166 ◽  
Author(s):  
Heli S. I. Hyry ◽  
Jussi P. Liippo ◽  
Hannele M. Virtanen
Keyword(s):  
Type 1 Diabetes ◽  
Contact Dermatitis ◽  
Allergic Contact Dermatitis ◽  
Glucose Sensors ◽  
Allergic Contact ◽  
Diabetes Patients

scholarly journals Acquired Leukoderma in a Patient with Allergic Contact Dermatitis to FreeStyle Libre®

2020 ◽  
Vol 78 (4) ◽  
pp. 381-384
Author(s):  
C. S. Queirós ◽  
M. I. Alexandre ◽  
P. M. Garrido ◽  
L. Soares de Almeida ◽  
T. Correia ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Contact Dermatitis ◽  
Allergic Contact Dermatitis ◽  
Medical Devices ◽  
Glucose Sensor ◽  
Diabetes Mellitus Type 1 ◽  
The Past ◽  
Freestyle Libre ◽  
Allergic Contact

In the past few years, the glucose sensor FreeStyle Libre® has been associated with several cases of allergic contact dermatitis. The allergen responsible for most of these cases is isobornyl acrylate, a substance present within the sensor that migrates through the adhesive, thereby reaching the skin. Acquired leukoderma, which may occur in an area previously affected by allergic contact dermatitis, has been described in several medical devices with adhesives. However, until the present, only one case of leukoderma induced by allergic contact dermatitis to FreeStyle Libre® has been described. We report the case of a 41-year-old woman with diabetes mellitus type 1, who developed leukoderma in association with allergic contact dermatitis to this glucose sensor.

The role of dupilumab in managing allergic contact dermatitis

2019 ◽  
Vol 3 (4) ◽  
pp. 234-238
Author(s):  
Andrew Desrosiers ◽  
Thy Huynh ◽  
Stephen Helms ◽  
Robert Brodell
Keyword(s):  
Contact Dermatitis ◽  
Allergic Contact Dermatitis ◽  
Limited Evidence ◽  
Immunological Responses ◽  
Type 2 Immune Response ◽  
Allergic Contact ◽  
The Cost ◽  
Systemic Therapies

Recently, there has been vigorous debate about the value of using dupilumab, a biologic that targets TH2-mediated processes, in the management of recalcitrant allergic contact dermatitis.  A review of the current literature found the following:  1) The cytokine polarity of the immunologic response in ACD depends upon the inciting allergen, so the therapeutic approach to ACD must be individualized; 2) a single allergen can elicit different immunological responses in patients with and without underlying AD; 3) there is limited evidence in support of using dupilumab for ACD in patients without concomitant AD; 4) the cost of this drug further argues against its use in all patients with ACD; 5) dupilumab’s benign side effect profile, particularly its lack of immunosuppression, relative to other systemic therapies make it a reasonable option in AD patients with systemic ACD to certain allergens known to elicit a significant type 2 immune response who have failed other treatments.

Sign in / Sign up

Export Citation Format

Share Document